ARIAD Pharma (ARIA) Ticks Higher Following Preliminary Ponatinib Phase 2 Data

ARIAD Pharmaceuticals (Nasdaq: ARIA) is trading higher early Monday morning, following preliminary data showing pan-BCR-ABL inhibitor, ponatinib, showing that 47 percent of chronic-phase CML patients in the trial achieved a major cytogenetic response to date, including 65 percent of patients who have a T315I mutation. Data were presented following a Phase 2 study. Click here for more.

Shares are up 3 percent ahead of the bell.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bausch + Lomb glaucoma eye drop fails Phase 2 trial
• Fate Therapeutics gets FDA clearance for FT839 CAR T-cell candidate
• NeoGenomics launches FDA-approved PTEN diagnostic test for prostate cancer